Fluoroquinolones: Blessings Or Curses

Author(s): Priyanka P. Majalekar*, Pramodkumar J. Shirote

Journal Name: Current Drug Targets

Volume 21 , Issue 13 , 2020


  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Fluoroquinolones are one of the world’s most valuable and popularly used categories of antimicrobial agents. This paper attempts to review the substantial progress of fluoroquinolones from their discovery to black box warning. Antibiotic drug choice will remain difficult in the presence of increasing resistance, but the introduction of fluoroquinolones has created a new and exciting era in antimicrobial treatment. These are a synthetic heterogeneous group of compounds used in both hospital and community practices to treat numerous severe infections. The era of quinolone antibiotics began with the serendipitous discovery of the quinolone prototype in 1962. The chronological development of fluoroquinolone reported that nalidixic acid was the first quinolone that gained popular choice for the treatment of urinary tract infection. The subsequent agents like levofloxacin, ofloxacin, norfloxacin, gatifloxacin, moxifloxacin, clinafloxacin, sparfloxacin, and ciprofloxacin were derived through side chain and nuclear manipulation from basic pharmacophore. The fluoroquinolone motifs have been found as a milestone, effective in certain infections that are respiratory tract infection, urinary tract infection, bone disorders, meningococcal and mycobacterial infections, sexually transmitted diseases, skin infections, etc. Fluoroquinolones are first entirely man-made antibiotics that exhibit antibacterial activity through the inhibition of topoisomerase II, topoisomerase IV and deoxyribonucleic acid gyrase, which is vital for chromosome replication and function. The post-marketing surveillance pointed out the favorable side effects associated with fluoroquinolones such as phototoxicity, QT interval prolongation and anaphylaxis. The discovery, development and clinical use of fluoroquinolone antibiotics in the last century contributed to a decline in morbidity and mortality rates.

Keywords: Fluoroquinolone, broad-spectrum antibiotic, chronological development, drug profile, black box warning, applications.

[1]
Chawan VS, Gawand KV, Badwane SV. Fluoroquinolones in India- Are we prescribing it right: A cost variation study. Natl J Physiol Pharm Pharmacol 2015; 5(4): 306-8.
[http://dx.doi.org/10.5455/njppp.2015.5.1604201547]
[2]
Emmerson AM, Jones AM. The quinolones: decades of development and use. J Antimicrob Chemother 2003; 51(Suppl. 1): 13-20.
[http://dx.doi.org/10.1093/jac/dkg208] [PMID: 12702699]
[3]
Redgrave LS, Sutton SB, Webber MA, Piddock LJ. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol 2014; 22(8): 438-45.
[http://dx.doi.org/10.1016/j.tim.2014.04.007] [PMID: 24842194]
[4]
Majalekar PP, Shirote PJ, Nalawade VV, et al. Design, synthesis and comparative pharmacological assessment of novel Fluoroquinolone derivatives. Int J Pharm Sci Res 2019; 10(8): 3735-40.
[5]
Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997; 25(5): 1213-21.
[http://dx.doi.org/10.1086/516116] [PMID: 9402384]
[6]
Hooper DC. Expanding uses of fluoroquinolones: opportunities and challenges. Ann Intern Med 1998; 129(11): 908-10.
[http://dx.doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00015] [PMID: 9867736]
[7]
Jackson MA, Schutze GE. COMMITTEE ON INFECTIOUS DISEASES. The use of systemic & topical fluoroquinolones. Pediatrics 2016; 138(5): e1-e13.
[http://dx.doi.org/10.1542/peds.2016-2706] [PMID: 27940800]
[8]
Murray TS, Baltimore RS. Pediatric uses of fluoroquinolone antibiotics. Pediatr Ann 2007; 36(6): 336-42.
[http://dx.doi.org/10.3928/0090-4481-20070601-09] [PMID: 17727139]
[9]
Velissariou IM. The use of fluoroquinolones in children: recent advances. Expert Rev Anti Infect Ther 2006; 4(5): 853-60.
[http://dx.doi.org/10.1586/14787210.4.5.853] [PMID: 17140360]
[10]
Sarkozy G. Quinolones: a class of antimicrobial agents. Vet Med 2001; 46: 257-74.
[http://dx.doi.org/10.17221/7883-VETMED]
[11]
Richards GA, Brink AJ, Feldman C. Rational use of the fluoroquinolones. S Afr Med J 2019; 109(6): 378-81.
[http://dx.doi.org/10.7196/SAMJ.2019.v109i6.14002] [PMID: 31266554]
[12]
Sprandel KA, Rodvold KA. Safety and tolerability of fluoroquinolones. Clin Cornerstone 2003; 5(3)(Suppl. 3): S29-36.
[http://dx.doi.org/10.1016/S1098-3597(03)90027-5] [PMID: 14992418]
[13]
Mandell L, Tillotson G. Safety of fluoroquinolones: An update. Can J Infect Dis 2002; 13(1): 54-61.
[http://dx.doi.org/10.1155/2002/864789] [PMID: 18159374]
[14]
Rubinstein E. History of quinolones and their side effects. Chemotherapy 2001; 47(S3)(Suppl. 3): 3-8.
[http://dx.doi.org/10.1159/000057838] [PMID: 11549783]
[15]
Epstein AB. Fluoroquinolones: the Next Generation. Review of Optometry 2003; 140(1): 1-7.
[16]
Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults Engl j med 2006; 354(13): 1352-61.
[http://dx.doi.org/10.1056/NEJMoa055191]
[17]
Bisacchi GS. Origins of the Quinolone Class of Antibacterials: An Expanded “Discovery Story”. J Med Chem 2015; 58(12): 4874-82.
[http://dx.doi.org/10.1021/jm501881c] [PMID: 25738967]
[18]
Rohlfing SR, Gerster JR, Kvam DC. Bioevaluation of the antibacterial flumequine for urinary tract use. Antimicrob Agents Chemother 1976; 10(1): 20-4.
[http://dx.doi.org/10.1128/AAC.10.1.20] [PMID: 984753]
[19]
Dalhoff A. In vitro activities of quinolones. Expert Opin Investig Drugs 1999; 8(2): 123-37.
[http://dx.doi.org/10.1517/13543784.8.2.123] [PMID: 15992068]
[20]
Bambeke FV, Michot JM, Eldere JV, et al. Quinolones in 2005 European society of clinical Microbiology and Infectious Diseases 2005; 11: 256-80.
[21]
Owens RC, Ambrose PG. Clinical use of the Fluoroquinolones Antibiotic therapy 2000; 84(60): 1447-69.https://www.ncbi.nlm.nih.gov/pubmed/12702699
[http://dx.doi.org/10.1016/S0025-7125(05)70297-2]
[22]
[https://en.wikepedia.org/wiki/Oxolinic_acid
[23]
[https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:138856
[24]
[https://pubchem.ncbi.nlm.nih.gov/compound/Oxolinic-acid
[25]
[https://www.drugbank.ca/drugs/DB00827
[26]
[https://en.wikipedia.org/wiki/Cinoxacin
[27]
Andersson MI, MacGowan AP. Development of the quinolones. J Antimicrob Chemother 2003; 51(S1)(Suppl. 1): 1-11.
[http://dx.doi.org/10.1093/jac/dkg212] [PMID: 12702698]
[28]
[https://pubchem.ncbi.nlm.nih.gov/compound/Miloxacin
[29]
[https://www.drugbank.ca/drugs/DB00817
[30]
[https://wiki2.org/en/Flumequine
[31]
[https://en.wikipedia.org/wiki/Flumequine
[32]
Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents 2000; 16(1): 5-15.
[http://dx.doi.org/10.1016/S0924-8579(00)00192-8] [PMID: 11185413]
[33]
[https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:75250
[34]
[https://pubchem.ncbi.nlm.nih.gov/compound/Pipemidic-acid
[35]
Goldstein EJ. Norfloxacin, a fluoroquinolone antibacterial agent Alliance Academ Int Med 1987; 82(6)(2): 3-17.https://www.ncbi.nlm.nih.gov/pubmed/3111257
[http://dx.doi.org/10.1016/0002-9343(87)90612-7]
[36]
Zaffiri L, Gardner J. Toledo-Pereyra1 LH. History of antibiotics: From fuoroquinolones to Daptomycin (Part 2). J Invest Surg 2013; 26: 167-79.
[http://dx.doi.org/10.3109/08941939.2013.808461] [PMID: 23869821]
[37]
[https://www.drugbank.ca/drugs/DB01165
[38]
[https://www.drugbank.ca/drugs/DB01208
[39]
Bertino J Jr, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000; 22(7): 798-817.
[http://dx.doi.org/10.1016/S0149-2918(00)80053-3] [PMID: 10945507]
[40]
[https://www.drugbank.ca/drugs/DB00537
[41]
[https://www.drugs.com/ciprofloxacin.html
[42]
Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989; 2(4): 378-424.
[http://dx.doi.org/10.1128/CMR.2.4.378] [PMID: 2680058]
[43]
[https://www.drugbank.ca/drugs/DB01137
[44]
[https://www.drugbank.ca/drugs/DB00218
[45]
O’Donnell JA, Gelone SP. The newer fluoroquinolones. Infect Dis Clin North Am 2004; 18(3): 691-716, x..
[http://dx.doi.org/10.1016/j.idc.2004.04.011] [PMID: 15308282]
[46]
[https://www.drugbank.ca/drugs/DB01044
[47]
Sharma PC, Jain A, Jain S. Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm 2009; 66(6): 587-604.
[PMID: 20050522]
[48]
Naber KG, Adam D. Classification of fluoroquinolones. Int J Antimicrob Agents 1998; 10(4): 255-7.
[http://dx.doi.org/10.1016/S0924-8579(98)00059-4] [PMID: 9916897]
[49]
Ball P. Quinolone generations: natural history or natural selection? J Antimicrob Chemother 2000; 46(Suppl T1): 17-24.
[http://dx.doi.org/10.1093/oxfordjournals.jac.a020889] [PMID: 10997595]
[50]
Scoper SV. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy. Adv Ther 2008; 25(10): 979-94.
[http://dx.doi.org/10.1007/s12325-008-0107-x] [PMID: 18836691]
[51]
Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 2002; 133(4): 463-6.
[http://dx.doi.org/10.1016/S0002-9394(02)01334-X] [PMID: 11931779]
[52]
Soni K. Fluoroquinolones: chemistry action-A review Indo glob 2012; 2(1): 42-53..http://iglobaljournal.com/wp-content/uploads/2012/05/4.-Kirti-Soni-2012.pdf
[53]
Tillotson GS. Quinolones: structure-activity relationships and future predictions. J Med Microbiol 1996; 44(5): 320-4.
[http://dx.doi.org/10.1099/00222615-44-5-320] [PMID: 8636945]
[54]
Das R, Mehta DK, Sharma V. Quinolones: Understanding the drug designing to combat drug resistance. Annals of Pharmacology and Pharmaceutics 2017; 2(9): 1-3.
[55]
Idowu T, Schweizer F. Ubiquitous nature of fluoroquinolones: The oscillation between antibacterial and anticancer activities. Antibiotics (Basel) 2017; 6(4): 1-24.
[http://dx.doi.org/10.3390/antibiotics6040026] [PMID: 29112154]
[56]
Bryskier A, Chantot JF. Classification and structure-activity relationships of fluoroquinolones. Drugs 1995; 49(Suppl. 2): 16-28.
[http://dx.doi.org/10.2165/00003495-199500492-00005] [PMID: 8549288]
[57]
Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry 2014; 53(10): 1565-74.
[http://dx.doi.org/10.1021/bi5000564] [PMID: 24576155]
[58]
Sood D, Kumar N, Singh A, Sakharkar MK, Tomar V, Chandra R. Antibacterial and pharmacological evaluation of fluoroquinolones: A cheoinformatics approach. Genomics Inform 2018; 16(3): 44-51.
[http://dx.doi.org/10.5808/GI.2018.16.3.44] [PMID: 30309202]
[59]
Vincent A. The quinolones: Past, present, future, Supplement article, Overview of quinolone development. Clin Infect Dis 2005; (41): (Suppl. 2): S113-9.
[60]
Schimizu M. Quinolone antibacterial agents: Their past, present, future. J Infect Chemother 1995; 1: 16-29.
[http://dx.doi.org/10.1007/BF02347726]
[61]
Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician 2002; 65(3): 455-64.
[PMID: 11858629]
[62]
Ko YH, Song PH. Current updates in and pharmacodynamics of fluoroquinolones. Korean J Urogenit Tract Infect Inflamm 2015; 10(1): 1-6.
[http://dx.doi.org/10.14777/kjutii.2015.10.1.1]
[63]
Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis 1998; 27(1): 33-9.
[http://dx.doi.org/10.1086/514623] [PMID: 9675446]
[64]
Norrby SR. Side-effects of quinolones: comparisons between quinolones and other antibiotics. Eur J Clin Microbiol Infect Dis 1991; 10(4): 378-83.
[http://dx.doi.org/10.1007/BF01967014] [PMID: 1864300]
[65]
Abou Heidar NF, Degheili JA, Yacoubian AA, Khauli RB. Management of urinary tract infection in women: A practical approach for everyday practice. Urol Ann 2019; 11(4): 339-46.
[http://dx.doi.org/10.4103/UA.UA_104_19] [PMID: 31649450]
[66]
Naber KG. Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents 2001; 17(4): 331-41.
[http://dx.doi.org/10.1016/S0924-8579(00)00362-9] [PMID: 11295418]
[67]
Andriole VT. Use of quinolones in treatment of prostatitis and lower urinary tract infections. Eur J Clin Microbiol Infect Dis 1991; 10(4): 342-50.
[http://dx.doi.org/10.1007/BF01967009] [PMID: 1864295]
[68]
Naber KG. Use of Quinolones in Urinary Tract Infections and Prostatitis Inf Dis 1989; II5: S1321-37.
[http://dx.doi.org/10.1093/clinids/11.Supplement_5.S1321]
[69]
Blondeau JM. Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections. Expert Opin Investig Drugs 2001; 10(2): 213-37.
[http://dx.doi.org/10.1517/13543784.10.2.213] [PMID: 11178338]
[70]
Shams WE, Evans ME. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. Drugs 2005; 65(7): 949-91.
[http://dx.doi.org/10.2165/00003495-200565070-00004] [PMID: 15892589]
[71]
Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implantrelated staphylococcal infections: A randomized controlled trial J Am Med Ass 1537; 279(19): 1537-41.
[72]
Li HK, Rombach I, Zambellas R, et al. OVIVA Trial Collaborators. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med 2019; 380(5): 425-36.
[http://dx.doi.org/10.1056/NEJMoa1710926] [PMID: 30699315]
[73]
Sarathy J, Blanc L, Alvarez-Cabrera N, et al. Fluoroquinolones efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations. Antimicrob Agents Chemother 2019; 63(5): 1-16.
[http://dx.doi.org/10.1128/AAC.02516-18] [PMID: 30803965]
[74]
Edlund C, Nord CE. Ecological effect of gatifloxacin on the normal human intestinal microflora. J Chemother 1999; 11(1): 50-3.
[http://dx.doi.org/10.1179/joc.1999.11.1.50] [PMID: 10078781]
[75]
Chen M, Guo Q, Wang Y, et al. Shifts in the antibiotic Susceptibility, Serogroups, and clonal complexes of Neisseria meningitidis in shanghai, china: A time trend analysis of the pre-quinolone and quinolone eras. PLoS Med 2015; 12(6)e1001838.
[http://dx.doi.org/10.1371/journal.pmed.1001838] [PMID: 26057853]
[76]
Cottagnoud P, Taube MG. Fluoroquinolones in the treatment of meningitis Cur infect Dis 2003; 5(329): 6.
[http://dx.doi.org/10.1007/s11908-003-0011-0]
[77]
Sendzik J, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents 2009; 33(3): 194-200.
[http://dx.doi.org/10.1016/j.ijantimicag.2008.08.004] [PMID: 18835137]
[78]
Ball P. Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review. Curr Ther Res Clin Exp 2003; 64(9): 646-61.
[http://dx.doi.org/10.1016/j.curtheres.2003.11.003] [PMID: 24944413]
[79]
Ball P. Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother 2003; 51(Suppl. 1): 21-7.
[http://dx.doi.org/10.1093/jac/dkg209] [PMID: 12702700]
[80]
Lewis T, Cook J. Fluoroquinolones and tendinopathy: a guide for athletes and sports clinicians and a systematic review of the literature. J Athl Train 2014; 49(3): 422-7.
[http://dx.doi.org/10.4085/1062-6050-49.2.09] [PMID: 24762232]
[81]
Golomb BA, Koslik HJ, Redd AJ. Fluoroquinolone-induced serious, persistent, multisymptom adverse effects. BMJ Case Rep 2015; 2015: 1-10.
[PMID: 26438672]
[82]
Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open 2015; 5(11)e010077.
[http://dx.doi.org/10.1136/bmjopen-2015-010077] [PMID: 26582407]
[83]
Choi SH, Kim EY, Kim YJ. Systemic use of fluoroquinolone in children. Korean J Pediatr 2013; 56(5): 196-201.
[http://dx.doi.org/10.3345/kjp.2013.56.5.196] [PMID: 23741232]
[84]
Mathews B, Thalody AA, Miraj SS, Kunhikatta V, Rao M, Saravu K. Adverse Effects of Fluoroquinolones: A retrospective cohort study in a south indian tertiary healthcare facility. Antibiotics (Basel) 2019; 8(3): 1-17.
[http://dx.doi.org/10.3390/antibiotics8030104] [PMID: 31357640]
[85]
Michalak K, Sobolewska-Włodarczyk A, Włodarczyk M, Sobolewska J, Woźniak P, Sobolewski B. Treatment of the fluoroquinolone - associated disability: The pathobiochemical implications. Oxid Med Cell Longev 2017.20178023935
[http://dx.doi.org/10.1155/2017/8023935] [PMID: 29147464]
[86]
Liu X, Ma J, Huang L, et al. Fluoroquinolones increase the risk of serious arrhythmias: A systematic review and meta-analysis. Medicine (Baltimore) 2017; 96(44)e8273
[http://dx.doi.org/10.1097/MD.0000000000008273] [PMID: 29095256]
[87]
Gorelik E, Masarwa R, Perlman A, et al. Fluoroquinolones and cardiovascular risk: A systematic review, meta-analysis and network meta-analysis. Drug Saf 2019; 42(4): 529-38.
[http://dx.doi.org/10.1007/s40264-018-0751-2] [PMID: 30368737]
[88]
Bolon MK. The newer fluoroquinolones Med clin N Am 2011; 95: 793-817.https://www.ncbi.nlm.nih.gov/pubmed/19909896
[http://dx.doi.org/10.1016/j.mcna.2011.03.006]
[89]
Sarro A, Sarro G. Adverse reactions to fluoroquinolones An overview on mechanistic aspects Cur med chem 2001; 8: 371-84.https://www.ncbi.nlm.nih.gov/pubmed/11172695
[90]
Molnar DM, Kremzner ME. Fluoroquinolones: A hot topic for pharmacists and the food and drug administration’s division of drug information. J Am Pharm Assoc 2019; 59(1): 13-6.
[PMID: 30348510]
[91]
Fernandez TD, Ariza A. Palomares. Hypersensitivity to fluoroquinolones. Med (Baltimore) 2016; 95(23)e3679
[92]
Khurana G, Arora S, Pawar PK. Ocular insert for sustained delivery of gatifloxacin sesquihydrate: Preparation and evaluations. Int J Pharm Investig 2012; 2(2): 70-7.
[http://dx.doi.org/10.4103/2230-973X.100040] [PMID: 23119235]
[93]
Rajalakshmi R, Padmaja C. Formulation and assessment of gemifloxacin mesylate ocular in situ gelling system. Int Res J Pharm 2013; 4(10): 33-8.
[http://dx.doi.org/10.7897/2230-8407.041009]
[94]
Gaikwad VD, Yadav VD, Gaikwad MD. Novel sustained release and swellable gastroretentive dosage form for ciprofloxacin hydrochloride. Int J Pharm Investig 2014; 4(2): 88-92.
[http://dx.doi.org/10.4103/2230-973X.133057] [PMID: 25006553]
[95]
Guguloth M, Bomma R, Veerabrahma K. Development of sustained release floating drug delivery system for norfloxacin: in vitro and in vivo evaluation. PDA J Pharm Sci Technol 2011; 65(3): 198-206.
[http://dx.doi.org/10.5731/pdajpst.2011.00685] [PMID: 22293231]
[96]
Chavanpatil MD, Jain P, Chaudhari S, Shear R, Vavia PR. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. Int J Pharm 2006; 316(1-2): 86-92.
[http://dx.doi.org/10.1016/j.ijpharm.2006.02.038] [PMID: 16567072]
[97]
Gupta H, Malik A, Khar RK, Ali A, Bhatnagar A, Mittal G. Physiologically active hydrogel (in situ gel) of sparfloxacin and its evaluation for ocular retention using gamma scintigraphy. J Pharm Bioallied Sci 2015; 7(3): 195-200.
[http://dx.doi.org/10.4103/0975-7406.160015] [PMID: 26229353]
[98]
El-Zahaby SA, Kassem AA, El-Kamel AH. Design and evaluation of gastroretentive levofloxacin floating mini-tablets-in-capsule system for eradication of Helicobacter pylori. Saudi Pharm J 2014; 22(6): 570-9.
[http://dx.doi.org/10.1016/j.jsps.2014.02.009] [PMID: 25561871]
[99]
Satyanandam S, Murala S. PH-Induced in situ gelling system of lomefloxacin for sustained ocular delivery. Int J Pharm Sci Drug Res 2015; 7(5): 1-4.
[100]
[https://www.hse.ie/eng/services/list/2/gp/antibioticprescribing/drug-interactions/fluoroquinolone-warning-2019.html
[101]
Tanne JH. FDA adds “black box” warning label to fluoroquinolone antibiotics. BMJ 2008; 337(7662): a816.
[http://dx.doi.org/10.1136/bmj.a816] [PMID: 18632714]
[102]
[https://www.medpagetoday.com/infectiousdisease/generalinfectiousdisease/73954


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 13
Year: 2020
Published on: 19 October, 2020
Page: [1354 - 1370]
Pages: 17
DOI: 10.2174/1389450121666200621193355
Price: $65

Article Metrics

PDF: 43
HTML: 2